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AbstrACt
Introduction Immunomodulators such as thiopurines 
(azathioprine (AZA)/6- mercaptopurine (6MP)), methotrexate 
(MTX) and biologics such as adalimumab (ADA) are well 
established for maintenance of remission within paediatric 
Crohn’s disease (CD). It remains unclear, however, which 
maintenance medication should be used first line in 
specific patient groups.
Aims To compare the efficacy of maintenance therapies 
in newly diagnosed CD based on stratification into high 
and low- risk groups for severe CD evolution; MTX versus 
AZA/6MP in low- risk and MTX versus ADA in high- risk 
patients. Primary end point: sustained remission at 12 
months (weighted paediatric CD activity index ≤12.5 and 
C reactive protein ≤1.5 fold upper limit) without relapse or 
ongoing requirement for exclusive enteral nutrition (EEN)/
steroids 12 weeks after treatment initiation.
Methods and analysis REDUCE- RISK in CD is an 
international multicentre open- label prospective 
randomised controlled trial funded by EU within the 
Horizon2020 framework (grant number 668023). Eligible 
patients (aged 6–17 years, new- onset disease receiving 
steroids or EEN for induction of remission for luminal ± 
perianal CD are stratified into low and high- risk groups 
based on phenotype and response to induction therapy. 
Participants are randomised to one of two treatment 
arms within their risk group: low- risk patients to weekly 
subcutaneous MTX or daily oral AZA/6MP, and high- risk 
patients to weekly subcutaneous MTX or fortnightly ADA. 
Patients are followed up for 12 months at prespecified 
intervals. Electronic case report forms are completed 
prospectively. The study aims to recruit 312 participants 
(176 low risk; 136 high risk).
Ethics and dissemination  ClinicalTrials. gov Identifier: 
(NCT02852694), authorisation and approval from 
local ethics committees have been obtained prior to 
recruitment. Individual informed consent will be obtained 
prior to participation in the study. Results will be published 
in a peer- reviewed journal with open access.
trial registration number NCT02852694; Pre- results.
IntroduCtIon
Crohn’s disease (CD), the most common 
form of inflammatory bowel disease (IBD) in 
children, is a chronic disorder with the poten-
tial to affect the whole gastrointestinal tract. 
The aim of CD treatment is to control active 
inflammation and achieve bowel healing. 
Chronic and uncontrolled CD results in poor 
outcomes for patients, including reduced 
quality of life, recurrent hospitalisation and 
potential need for surgical intervention.1 
strengths and limitations of this study
 ► This is the first international prospective randomised 
controlled trial comparing three different medica-
tions for maintenance of remission in newly diag-
nosed Crohn’s disease.
 ► This study may better define the most appropriate 
first- line immunomodulators based on a risk strat-
ification protocol.
 ► Therapeutic efficacy will be supported by drug lev-
els, pharmacogenomics and microbiome analysis as 
secondary outcomes.
 ► Inability to blind participants or treating physicians 
serves as a limitation to this study.
 ► Blinding of an alternative clinician to assess disease 
activity during study visits may prove practically dif-
ficult in smaller centres.  on A
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Table 1 Definition of high- risk patients based on ECCO/ESPGHAN consensus guidelines
Defining high- risk Crohn’s disease patients
ECCO/ESPGHAN consensus guidelines Modified study criteria
Severe perianal disease Complex perianal fistulising disease phenotype
Extensive (pan- enteric) disease; deep colonic ulcers on 
endoscopy
Panenteric disease phenotype (defined as L3 with L4b as per 
Paris classification25 or L3 with deep ulcers in the duodenum, 
stomach or oesophagus not related to non- steroidal anti- 
inflammatory medications or Helicobacter pylori)
Overall cumulative disease extent of >/=60 cm
Stricturing and penetrating disease at onset B2, B3 or B2B3 disease behaviour20
Marked growth retardation ≥2.5 height Z scores Severe growth impairment (height z- score ≤2 or crossing ≥2 
centiles) likely related to Crohn’s disease
Persistent severe disease despite adequate induction 
therapy
Hypoalbuminaemia (<30 g/L), elevated CRP (at least two times 
upper limit of normal range), or wPCDAI >12.5 despite at least 3 
weeks of optimised induction therapy with steroids or EEN
Severe osteoporosis Not included
CRP, C reactive protein; ECCO, European Crohn’s and Colitis Organisation; EEN, exclusive enteral nutrition; ESPGHAN, European Society for 
Paediatric Gastroenterology, Hepatology and Nutrition; wPCDAI, weighted Paediatric Crohn’s Disease Activity Index.
Treatments for CD are categorised into those which 
induce remission (such as steroids1 2 or exclusive enteral 
nutrition (EEN)1 3 and those which maintain remission. 
Immunomodulators are a mainstay of maintenance treat-
ment in IBD, with the efficacy of thiopurines (eg, azathi-
oprine (AZA) and 6- mercaptopurine (6MP))4–6 and 
methotrexate (MTX)7–10 well established. Antitumour 
necrosis factor (anti- TNF) therapies (infliximab11 12 and 
adalimumab (ADA)13 14 including their biosimilars were 
used in those patients refractory to ‘traditional’ induc-
tion or maintenance treatment. More recently in clinical 
practice, patients deemed as high risk have been treated 
with a biologic without the need for prior use of an 
immunomodulator.
Due to a lack of treatment strategy trials within the 
paediatric IBD (PIBD) population, however, it remains 
unclear which of the aforementioned maintenance ther-
apies should be used first line in individual patients. 
Randomised controlled trials (RCTs) comparing the use 
of MTX with thiopurines for maintenance of remission 
failed to show a significant difference in efficacy between 
the two.15–17 A Cochrane review in adults with quiescent 
CD highlighted the lack of adequately powered trials 
necessary in order to determine the efficacy and safety 
of thiopurines compared with other maintenance thera-
pies.4 10 The RISK study (observational, non- randomised 
study) demonstrated improved clinical and growth- 
based outcomes at 1 year with anti- TNF monotherapy in 
comparison with immunomodulators; however, further 
investigation into which specific patients are most likely 
to benefit from these therapies is still required.18 There 
is a clear disparity between North America and Europe 
in terms of which form of immunosuppression is used 
initially with both concerns about efficacy and safety lying 
behind these differences, thus, there is an urgent need 
for a head to head study in children to help objectively 
inform the primary choice of immunosuppression.
Stratifying patients by risk for complex or severe CD 
may allow pre- emptive direction of maintenance strategy 
and potentially an early reduction in disease burden 
with subsequent improvement in long- term outcomes. 
The adult IBD Ahead initiative highlighted young age at 
diagnosis as a risk factor for severity of CD evolution19; all 
patients diagnosed within paediatric services would there-
fore be considered ‘high risk’. Paediatric consensus guide-
lines suggest that paediatric CD patients at ‘high risk for 
poor outcome’ should receive early therapy optimisation 
to modify progression of their disease.1 The guidelines 
list specific features which may be considered predictive 
for poor outcome in paediatric CD (see table 1).1 Patients 
deemed at high risk for complex disease or poor outcome 
may benefit from a ‘top- down’ approach as the TISKids 
(an RCT from disease diagnosis) aims to investigate.20
Therefore, the PIBDnet consortium recognised the 
urgent need to investigate the efficacy and safety of immu-
nomodulators and to investigate whether a top- down 
approach was superior to a traditional ‘step- up’ for paedi-
atric patients deemed at high risk for rapidly complicated 
disease course. REDUCE- RISK in CD is an RCT which 
aims to compare the effectiveness of immunomodulators 
for maintenance of remission in newly diagnosed CD 
based on risk stratification specifically, the effectiveness 
of MTX versus AZA/6MP for maintenance of remission 
who are low risk for rapidly progressive disease and the 
effectiveness of MTX versus ADA in a high- risk group.
MEthods And AnAlysIs
study design
We designed an international multicentre open- label 
prospective RCT with four treatment arms as shown 
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Figure 1 Study design of the REDUCE- RISK in CD trial. M2=month 2, V2=visit 2. EN, enteral nutrition; PCDAI, Paediatric 
Crohn’s Disease Activity Index; PGA, physician global assessment; wPCDAI, weighted PCDAI.
in figure 1. Following screening and consent, eligible 
patients are stratified into low and high- risk groups 
based on phenotype and disease response to induction 
therapy (table 1). Patients are then randomised to one 
of two arms within their risk group, with low- risk patients 
receiving either weekly subcutaneous MTX or daily oral 
AZA/6MP and high- risk patients receiving either weekly 
subcutaneous MTX or fortnightly subcutaneous ADA.
study end points
Patients are followed up for 12 months postrandomi-
sation. The primary end point of the study is sustained 
steroid or EEN- free remission at 12 months, defined 
as weighted Paediatric Crohn’s Disease Activity Index 
(wPCDAI) ≤12.5 and C reactive protein (CRP) ≤1.5 fold 
upper limit without a relapse or need for EEN/steroids 
since week 12.
Secondary end points include comparison of time 
to first relapse, remission at 12 weeks, growth, adverse 
events, health- related quality of life and patient- reported 
outcomes between the two treatment arms within each 
risk group but also between low and high risk MTX 
treated patients (a full list of secondary endpoints 
can be found in box 1). The TUMMY CD (patient- 
related outcome measure) was originally included as 
a secondary end point but has been withdrawn as the 
original timetable of development and validation of the 
score has not been met so it was not ready in time to 
be included. The study also aimed to evaluate clinical 
predictors for response, including genomic and sero-
logical markers and results of drug monitoring (MTX 
and ADA concentrations) metabolites (6- thioguanine 
(6- TG) and 6- methylmercaptopurine (6- MMP) in 
AZA/6MP) and antidrug antibodies (ADA) in rela-
tion to adherence, toxicity and response. The ancil-
lary study additionally aimed to evaluate the efficacy 
of ADA in patients treated from inclusion (top- down) 
versus patients switched to ADA due to immunomodu-
lator failure (step- up). Further outcome measures are 
detailed in box 1.
Eligibility criteria and recruitment
Full eligibility criteria for the study are listed in box 2. 
Patients are eligible if aged 6–17 years with new- onset (<6 
months) treatment naïve luminally active and/or perianal 
fistulising CD diagnosed as per revised Porto criteria21 
receiving steroids or EEN for induction of remission with 
wPCDAI >40 or CRP >2 times upper limit of normal at 
diagnosis. Eligible definitions of disease behaviour were 
derived from the Paris classification.22 Informed consent 
from must be obtained prior to participation in the study. 
Patients are excluded in cases of previous use of IBD- 
related medications, pregnancy or refusal to use contra-
ceptives; disease requiring surgery, contraindications 
to study medication, exposure to live vaccine within 3 
weeks, oral anticoagulant or antimalarial use, current or 
previous malignancy, significant infection or significant 
comorbidity.
The planned start date for the study is January 2017 
with planned end June 2022.
 on A
ugust 21, 2020 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-034892 on 1 July 2020. D
ow
nloaded from
 
4 Harris RE, et al. BMJ Open 2020;10:e034892. doi:10.1136/bmjopen-2019-034892
Open access 
box 1 study endpoints
Primary endpoint
 ► Sustained steroid/exclusive enteral nutrition (EEN)- free remission 
at month 12, where sustained remission is defined as weighted 
Paediatric Crohn’s Disease Activity Index (wPCDAI) ≤12.5 and C re-
active protein (CRP) ≤1.5 times the upper limit without a relapse or 
need for EEN/steroids since week 12.
Secondary endpoints
Comparing the following within (1) the two treatment arms per risk 
group; (2) methotrexate treatment between high and low- risk groups 
and (3) tOP- down adalimumab (high- risk group) versus step- pp adali-
mumab (ancillary study):
 ► Rate of clinical remission at month 12 (physician global assessment, 
wPCDAI, PCDAI).
 ► Relapse free remission with normal CRP at month 12.
 ► Relapse- free remission with normal CRP and faecal calprotectin 
<300 at month 12.
 ► Remission at week 12 (measured by wPCDAI≤12.5 and normal CRP 
and being off steroids/EEN).
 ► Time to first relapse after week 12.
 ► Predictive value of faecal calprotectin values at visits 1, 2, 4 and 6 
(respectively at month 0, 2, 6 and 12).
 ► Drop- out rates.
 ► Adverse drug event rate including pharmacogenomics for toxicity 
and response to therapy.
 ► Height velocity and z- score at baseline and 52 weeks.
 ► Quality of life as measured by the IMPACT 3 questionnaire complet-
ed at each study visit.
 ► Health economic evaluation at all visits (forms EQ- 5D- Y proxy 1, 
EQ- 5D- Y and EQ- 5D- 5L, Productivity and Activity Impairment 
Questionnaire (WPAI):Crohn’s disease Caregiver, School Attendance 
start of the research and follow- up visits).
box 2 Eligibility criteria
Inclusion criteria
 ► Patients aged 6–17 years with new- onset (<6 months) treatment 
naïve active luminal and/or perianal fistulising Crohn’s disease di-
agnosed using established criteria21 requiring steroids or exclusive 
enteral nutrition (EEN) for induction of remission weighted Paediatric 
Crohn’s Disease Activity Index (wPCDAI) >40 or C reactive protein 
(CRP) >2 times upper limit of normal at diagnosis.
 ► Luminal active Crohn’s disease (B1) with or without B2 and/or B3 
disease behaviour as per Paris classification.22
 ► Signed informed consent.
Exclusion criteria
 ► wPCDAI <42.5 at diagnosis, except where CRP >2 times upper nor-
mal limit.
 ► Lack of induction therapy with steroids or EEN.
 ► Previous therapy with any inflammatory bowel disease- related 
medication other than induction therapy as detailed within this pro-
tocol with the exception of 5- aminosalicylic acid preparations.
 ► Pregnancy or refusal to use contraceptives during the study period 
in pubertal patients unless absolute abstinence is confirmed at each 
study visit.
 ► Lactating mothers.
 ► Perianal fistulising disease requiring surgical therapy.
 ► Patients homozygous for thiopurine methyltransferase (TPMT) mu-
tations or those with TPMT activity <6 nmol/hour/mL erythrocytes or 
<9 nmol 6- methyl thioguanine (6MTG)/g Hb/hour, unless they qual-
ify as high- risk patients.
 ► Evidence of undrained and uncontrolled abscess/phlegmon.
 ► Contraindication to any drugs used in the trial (including intolerance/
hypersensitivity or allergy to study drugs (thiopurines, methotrexate 
or adalimumab)).
 ► Current or previous malignancy.
 ► Serious comorbidities (eg, renal insufficiency, hepatitis, respiratory 
insufficiency) which may interfere with drug therapy or interpreta-
tion of outcome parameters or will make it unlikely that the patient 
will complete the trial.
 ► Infection with mycobacterium tuberculosis, hepatitis B or C, HIV.
 ► Moderate to severe heart failure (New York Heart Association class 
III/IV).
 ► Oral anticoagulant therapy, antimalarial therapy.
 ► Live vaccine exposure (including yellow fever) less than 3 weeks 
prior to inclusion.
Screening visit (visit 0)
The screening visit allows for assessment of eligibility for 
inclusion in the study, evaluation of the patient’s response 
to induction therapy if already commenced, commence-
ment of induction therapy where not commenced, and 
acquisition of consent and assent.
Induction therapy
All enrolled patients receive either corticosteroids or EEN 
as induction as determined by the clinical team and the 
patient/caregiver. For EEN any balanced formula (poly-
meric or elemental) administered orally or via nasogastric 
tube is permitted and should be prescribed for 6–8 weeks. 
Tapering of steroids is at the discretion of the prescribing 
clinician. Adaptation of induction therapy (eg, dose 
increase of steroids or return to EEN) or crossover from 
one induction therapy to the other is permitted in order 
to achieve remission, however, patients must have discon-
tinued their induction therapy by week 12. If induction 
therapy is not discontinued by week 12, the patient is 
considered a treatment failure, with the protocol for this 
detailed below.
Inclusion visit and risk group allocation (week 5±3 weeks; visit 1)
In order to incorporate response to initial induction 
therapy within the risk stratification criteria, inclusion 
and risk group allocation is performed at week 5±3 weeks 
of induction therapy. Data from the screening visit are 
reviewed with ineligible patients excluded and patients 
are then stratified into the high or low risk group (table 1) 
based on the European Crohn’s and Colitis Organisation/
European Society for Paediatric Gastroenterology, Hepa-
tology and Nutrition consensus guidelines.1 Patients with 
perianal fistulising disease at diagnosis are auto allocated 
to the high- risk group regardless of other factors at inclu-
sion visit. All other patients are allocated to the low- risk 
group. Patients with low thiopurine methyltransferase 
(TPMT) activity or homozygous mutations are excluded 
should they be categorised as low risk.
randomisation and treatment allocation
Randomisation is undertaken following allocation to high 
or low- risk group at week 5±3 weeks. This process uses an 
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Table 2 Medication protocol for low and high- risk patients following randomisation
Therapy Route Dose Notes
Low risk protocol Methotrexate SC 15 mg/m2 body surface area weekly (max 
dose 25 mg).
Ondansetron 4–8 mg orally 1- hour 
preinjection and folic acid 15 mg (5 mg in 
patients <20 kg) 3 days postinjection are 
recommended for all patients.
Versus
Azathioprine PO 2.5 mg/kg (rounded down to nearest 
12.5 mg).
Half calculated dose for TPMT 
heterozygotes/activity 6–9 nmol/hour/mL.
OR
6- Mercaptopurine PO 1.5 mg/kg (rounded down to nearest 
12.5 mg).
Half calculated dose for TPMT 
heterozygotes/activity 6–9 nmol/hour/mL.
High- risk protocol Methotrexate SC 15 mg/m2 body surface area weekly (max 
dose 25 mg).
Ondansetron 4–8 mg orally 1- hour 
preinjection and folic acid 15 mg (5 mg in 
patients <20 kg) 3 days postinjection are 
recommended for all patients.
Versus
Adalimumab
(Humira)
SC 160 mg then 80 mg after 2 weeks then 
40 mg every 2 weeks thereafter (patients 
>35 kg).
120 mg then 80 mg after 2 weeks then 
40 mg every 2 weeks thereafter (patients 
25–35 kg).
80 mg then 40 mg after 2 weeks and 
20 mg every 2 weeks thereafter (patients 
<25 kg).
PO, Oral; SC, subcutaneous; TPMT, thiopurine methytransferase.
integrated module within the electronic case report form 
(CRF) system. Within both the high and low- risk groups 
patients are 1:1 randomised to MTX vs ADA or AZA/6MP, 
respectively, in blocks of four stratified by EEN or steroid 
induction therapy. Code for randomisation is prepared 
and held by the central coordinating site and site coordi-
nators are then informed of the results. Immunomodu-
lator or biological therapy should be commenced within 
2 weeks of randomisation as per the protocol outlined in 
table 2.
AZA/6MP and MTX are prescribed and dispensed 
according to local guidelines. ADA (Humira) is provided 
by AbbVie. Cointerventions are prohibited.
Follow up visits (visit 2, 3, 4, 5 and 6)
Patients are followed up at prespecified intervals 
(figure 1) with a window of ±2 weeks. A telephone call 
is undertaken at week 4 following initiation of induction 
in order to support patient compliance with induction 
regime and advise weaning where appropriate. Data as 
described in box 3 are collected at each consultation. 
Patients’ compliance with therapy is determined at each 
face- to- face follow- up visit by pill and vial counts plus by 
patients’ reporting.
Remission is defined as wPCDAI≤12.5, normal CRP 
(≤1.5 times upper normal range) and being free of 
steroids or EEN. Once remission is achieved and induc-
tion therapy is discontinued, a patient is considered to 
be failing treatment or experiencing a relapse in the 
following circumstances:
 ► wPCDAI >40.
 ► CRP >2 times upper normal limit in the absence of 
any clear infectious process.
 ► wPCDAI >12.5 but <40 and/or CRP >1.5 times but <2 
times over upper normal limit at two consecutive visits 
within 2–8 weeks.
 ► Development of CD- related complications, for 
example, fistulisation.
 ► Requirement for additional CD- specific medication/
surgery since last study visit.
A patient will also be considered a treatment failure 
should induction therapy be continued at week 12. In 
addition, the treating clinician may escalate treatment at 
any time point independent of wPCDAI score if it is felt 
that the patient is experiencing a relapse.
Dose optimisation and therapeutic drug monitoring
Drug monitoring is undertaken as detailed below. In 
addition to this, samples for drug monitoring should be 
collected at the time of medication cessation in the event 
of drug discontinuance due to adverse effect or loss of 
response. Potential adaptations to therapies which may 
be made at specific follow- up visits are detailed in box 4.
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box 3 standard requirements for each study visit
 ► An explicit history of illness since last visit, including review of 
symptoms, medications (including compliance check) and adverse 
events.
 ► Physical examination weighted Paediatric Crohn’s Disease Activity 
Index (wPCDAI), physician global assessment and PCDAI scoring.
 ► Anthropometrics (height measured using a calibrated wall mounted 
stadiometer).
 ► Blood tests.
 – White blood cells.
 – Absolute neutrophil count.
 – Haemoglobin.
 – Haematocrit.
 – Platelet count.
 – Erythrocyte sedimentation rate.
 – C reactive protein.
 – Amylase.
 – Albumin.
 – Aspartate transaminase.
 – Alanine transaminase.
 – Conjugated bilirubin.
 – Gamma glutamyl transferase.
 ► Stool samples for faecal calprotectin and microbiome analysis.
 ► Health economic parameters (EQ- 5D- Y proxy 1; EQ- 5D- Y; EQ- 5D- 
5L; WPAI:Crohn’s disease; school attendance questionnaire).
 ► Quality of life evaluation (IMPACT 3).
 ► Urine human chorionic gonadotropin in all female patients of child-
bearing potential.
 ► Confirmation of contraception use or of absolute abstinence in all 
patients.
box 4 Potential adaptations to therapies at follow- up 
visits
Month 2 (visit 2)
 ► Failure to discontinue induction therapy by week 12
 – Offer switch to the ancillary study (adalimumab (ADA) step- up) 
to those prescribed methotrexate (MTX) or azathioprine (AZA)/6- 
mercaptopurine (6MP), or an increase in dose frequency to 
weekly in those prescribed ADA.
 – Alternatively, the patient may leave the study and receive thera-
pies as per the discretion of the treating clinician.
Months 4, 6, 9 and 12 (visits 3, 4, 5 and 6)
 ► Thiopurine non- response.
 – Protocol as per metabolite levels (detailed in table 3).
 ► Thiopurine intolerance (except pancreatitis).
 – Switch to alternate thiopurine (AZA to 6MP or vice versa) or split 
dose to provide twice daily (BD) dosing.
 ► Thiopurine failure (any exacerbation despite dose optimisation/
pancreatitis/cytopaenia).
 – Offer switch to ancillary study (ADA STEP- up) or exit study.
 ► MTX intolerance or failure (any exacerbation or elevation of liver 
enzymes as detailed below).
 – Offer switch to ancillary study (ADA STEP- up) or exit study.
 ► ADA failure (any exacerbation).
 – Increase frequency to weekly dosing.
Table 3 Azathioprine dose adjustments based on 
metabolite levels
Result Action
6- TG <150 Consider non- compliance; repeat 
sample at subsequent visit 
and increase dose if low 6- TG 
confirmed (+25 mg or +12.5 mg if 
dose <50 mg).
6- TG 150–800 No adaptation.
6- TG >800 Decrease dose if repeat sample 
at subsequent visit confirms high 
6- TG (−25 mg or −12.5 mg if dose 
<50 mg).
6- MMP >8000 or signs 
of hepatotoxicity
Stop medication—switch to 
ancillary study.
Erythrocyte lysate sample frozen 
at −80°C and shipped to central 
lab at end of study for thiopurine 
nucleotides.
6- MMP, 6- methylmercaptopurine.
Azathioprine
TPMT genotype or phenotype at screening determines 
the initial dose of AZA/6MP; and measurement of thiopu-
rine metabolites (6- TG and 6- MMP) at visit 2 determines 
requirement for subsequent dose adjustment performed 
according to the recommendations in table 3. Where 
possible thiopurine metabolites are measured locally; 
central lab measurements are provided for centres where 
this is unavailable.
At visit 2, a urine sample for TPMT metabolite determi-
nation and an erythrocyte lysate sample for quantification 
of thiopurine nucleotides by liquid chromatography- 
tandem mass spectrometry should be frozen at −80°C and 
shipped on dried ice to the central lab at the end of the 
study. At each visit from visit 2–6, an additional ethylene-
diaminetetraacetic acid (EDTA) blood sample will be 
collected for further 6- TG and 6- MMP testing and frozen 
at −80°C.
Methotrexate
Washed erythrocyte for MTX levels will be obtained at 
visits 2, 4 and 6 and stored frozen at local centres. These 
samples will be sent on dry ice for central analysis to eval-
uate response to therapy and adverse effects in relation 
to drug levels.
Adalimumab
ADA trough levels are measured after three injections of 
maintenance therapy (eg, at visit 2) within the local labo-
ratory (central lab testing available if local lab testing is 
unavailable). Dosing interval may be shortened to weekly 
in the event of low ADA levels (<8 μg/mL) and negative 
ADA antibodies. Further samples should be obtained at 
visits 3, 4, 5 and 6 and should be frozen for later analysis 
within the central lab.
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box 5 Criteria for premature termination of study 
treatment or participation
 ► Pregnancy at any stage.
 ► Treatment failure as per protocol.
 ► Failure to tolerate allocated treatment or alternatives as listed within 
the protocol.
 ► Significant drug- related side effects manifesting as significantly 
abnormal bloods results or adverse effects based on the clinical 
judgement of the treating physician.
 ► Request of participant to be withdrawn from treatment.
 ► The judgement of the treating physician being that it is in the best 
interests of the participant to withdraw from study treatment.
 ► Loss of participant to follow- up.
 ► Patient death.
Pharmacogenetics
DNA for pharmacogenetics should be taken from 
patients randomised to MTX or AZA/6MP for multiplex 
genotyping of polymorphism related to drug metabolism 
to evaluate safety and response to therapy. Analysis will 
be performed at the end of the study, or earlier in those 
patients showing toxicity.
Ancillary study
Patients unable to discontinue induction therapy or those 
randomised to thiopurine or MTX therapy who experi-
ence treatment failure may be invited to participate in 
the ancillary study (STEP- up ADA) until visit 5. Any initial 
maintenance therapy will be stopped and induction and 
maintenance regime for ADA as previously described 
will be commenced. Up to three additional study visits 
at 3- month intervals will be offered to these patients in 
order to obtain 12 months of follow- up. A maximum of 68 
patients can participate in this ancillary study allowing a 
1:1 comparison of top- down ADA to step- up ADA therapy.
Unscheduled visits
Unscheduled visits may be arranged based on clinical 
requirements. As for scheduled visits per protocol treat-
ment adaptions are possible if intolerance or failure of 
the study drug is detected. Subsequent scheduled visits 
will not be changed after an unscheduled visit.
Treatment discontinuation
Patients who discontinue treatment before completing 12 
months of study drug within either the main study or the 
ancillary study will receive a single follow- up visit. This will 
be either 12 months after the commencement of study 
treatment or at the point of inclusion in the ancillary study.
Modifications to the protocol while the study is being 
conducted will be relayed to all site staff by email and 
then onto their relevant ethical and regulatory boards. 
The current manuscript is based on protocol 5.1 last 
modified 28 May 2019.
Allocation concealment and blinding
For ethical reasons, we decided against a double dummy 
design for blinding the patient, parents and care givers. 
Due to the differences in medication administration route 
and the significant nausea commonly associated with MTX 
blinding of the allocation to the patients, their families or 
their physicians is not possible. Where possible, however, 
blinding of an alternative clinician to score the wPCDAI, 
PCDAI and physician global assessment at each study visit 
should occur (prospective randomised open blind end- 
point (PROBE) evaluation).
safety
The external and independent advisory board of PIBD-
SETQuality serves as an independent data and safety moni-
toring board which meets at prespecified intervals with 
access to all data within the study. The principal investigator 
at each site is responsible for reporting any safety issues 
(adverse events, serious adverse events (SAEs), suspected 
unexpected serious adverse reactions), drop- outs or any 
new information which may impact the study in any way. 
The principal investigator shall report to the sponsor all 
SAEs experienced by a study subject receiving an ADA 
(Humira) within 24 hours of learning of the event regard-
less of the relationship of the event to the product. All SAEs 
are immediately sent to AbbVie pharmacovigilance by the 
sponsor. SAEs will be followed from the date of patient’s 
signature of informed consent, until complete resolution 
or 30 days after the end of the study/patient’s final study 
visit.
Participants may withdraw consent for further participa-
tion or data collection at any time without giving reason 
and without prejudicing further care or treatment. Patients 
will be permanently withdrawn from study treatment in the 
event of any of the situations outlined in box 5. Patients 
should be provided with a study alert card for use in the 
event of an emergency.
Biochemical markers are monitored with a clearly 
defined protocol for adjustments to therapy based on 
abnormal results (eg, neutropenia, pancreatitis, elevated 
liver enzymes).
data collection, management and monitoring
Patient CRFs are completed in a prospective manner using 
an electronic web- based system designed specifically by 
PIBDnet for this trial. In order to maintain data security 
and integrity, the web- based data entry will be linked to a 
password- secured Microsoft Access database, where data 
will be stored until time of analysis. Files will be saved on a 
code secured net- drive and backed- up following each data 
entry on a disk locked in a cabinet. Patients will be identi-
fied only by a study code assigned at the point of enrolment. 
Code of patient identifiers will be kept at each participating 
site. Handling of patient- identifiable is compliant with the 
legislation of each participating centre and the European 
General Data Protection Regulation. Investigators will be 
invited to fax or email the paper source document to the 
coordinating site on a random basis to allow appropriate 
monitoring. Access to data with detailed information on 
study outcomes will be made available to other research 
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groups on request and at the discretion of the principal 
investigators.
Monitoring arrangements are in place for all sites after 
initial site initiation. The monitoring visits will occur regu-
larly partly dependant on recruitment rate at individual 
sites. The monitoring is performed usually by someone 
external to the clinical team.
Analysis and statistical methods
Descriptive statistics (mean, median, SD, SE, quartiles, 
minimum, maximum and two- sided 95% confidence limits 
of mean and median) will be presented for each treat-
ment of the low and high- risk paediatric CD groups and 
where applicable, for the paired difference of each patient. 
Frequency tables will be presented where applicable.
Primary analysis
Difference in the 12- month steroid/EEN free sustained 
remission rates between the treatment groups will be 
undertaken using X2 test. Mantel- Haenszel test will be used 
to combine data from all participating sites.
secondary analyses
X2 tests or Fisher’s exact tests will be used to compare rates 
of remission, steroid intake, drop- out and SAEs between 
the two arms of each risk group and between the low and 
high- risk MTX groups. Logistic regression analyses may be 
performed to adjust for any imbalances in baseline covari-
ates. To compare time to disease flare between the arms 
of each risk group and between high and low- risk MTX 
groups, a Kaplan- Meier survival estimate will be used and 
the log- rank test of equality over strata. A Cox proportional 
hazard model will be constructed to obtain a HR after vali-
dation of the proportionality assumption and adjusting for 
possible confounding variables (including age and disease 
duration). Student’s t tests or Wilcoxon rank sum tests will 
be used to compare growth, steroid dose, adverse events, 
changes in quality of life and patient reported outcomes 
between the two arms of each risk group and between the 
high and low- risk MTX groups. The predictive value of 
faecal calprotectin levels, CRP, serum tests or other clin-
ical predictors for response (including genomic and sero-
logical markers) will be assessed for each arm of the study 
using sensitivity, specificity, negative and positive predictive 
values or area under the receiver operating characteristic 
curve. Multivariate logistic regression analyses will then be 
performed.
Analyses will be performed using the R software (http:// 
cran. r- project. org). All comparisons will be made using a 
two- sided significance level of 0.05.
Sample size considerations
Estimated remission rates are based on recent analysis from 
the RISK study,18 indicating an advantage of early anti- TNF 
introduction over immunomodulator therapy. For the low- 
risk group, it was hypothesised that 48% of children will be 
in remission at 12 months for the AZA/6MP arm versus 
70% for the MTX arm. On the basis of this data with an 
alpha risk of 5% and a power of 80% a sample requirement 
of 88 patients per arm was calculated assuming a 10% lost to 
follow- up. For the high- risk group, it was hypothesised that 
40% of children will be in remission at 12 months for the 
MTX arm versus 65% for the ADA arm. To detect this differ-
ence with an alpha risk of 5% and a power of 80%, a sample 
size of 68 participants is necessary, again assuming a 10% 
lost to follow- up. In total 312 participants will be included in 
the study (176 low- risk group; 136 high- risk group).
Patient and public involvement
Patients were not involved in the development of this study; 
however, the French patient charity AFA Crohn, RCH, 
France was involved in study design and critically reviewed 
and commented on all aspects of the trial.
discussion
REDUCE- RISK in CD is the first multicentre international 
RCT aiming to compare three different medication strate-
gies for maintenance of remission in newly diagnosed CD 
based on a risk stratification protocol. During the 12- month 
follow- up period, the effects of the differing management 
strategies will be assessed via data collected and outcome 
measures as defined above in order to analyse the efficacy 
and safety of each medication and better define the most 
appropriate first- line maintenance immunomodulators 
to be used in specific subsets of CD patients. As a group 
we speculatively hypothesise that MTX will be superior to 
thiopurines for maintaining remission in CD in the low- 
risk group although in the absence of head to head studies 
prior to this one this study will provide randomised data to 
address this. Additionally, from our own work and others, 
we know response to induction therapy is an important 
prognostic marker and we wanted to allow the induction 
treatment to have a chance to work before we assigned 
high or low risk status.23 24 Thus, it was a pragmatic compro-
mise with the timing of introduction of the maintenance 
treatment to give the induction treatment long enough to 
show its effect while recognising both treatments have a ‘lag 
period’ of a few weeks before they become fully effective.
We also hypothesise that ADA will be superior to MTX 
in the high- risk group based on the results from the RISK 
study.18 Of note ADA (Humira) was chosen to allow delivery 
of the study out of hospital, to reduce drug costs and it 
allowed single therapies to be compared with each other. 
Practically if we had used infliximab (Remicade) then we 
would have needed to use combination therapy which we 
did do not want to do as it would have further complicated 
the trial design.
In addition to this, the ancillary study will compare 
outcomes in ADA treated patients from inclusion (top- 
down) versus patients switched to ADA due to failure of 
immunomodulators (step- up), with the potential to stratify 
which patients might benefit from such a top- down treat-
ment strategy. We acknowledge that comparison of the 
ancillary group with the group randomised from baseline 
to ADA is not randomised and may be subject to selection 
bias noting the ancillary group have failed or been intol-
erant to initial therapy. However, we feel it is important to 
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include this to allow us to compare the trial with studies 
which have allocated patients directly to anti- TNF (RISK, 
TISKids) and to see how many patients benefit from ‘rescue 
therapy’ after failure of their initial allocation.
The design and completion of interventional studies in 
PIBD is a recognised challenge between rigorous study 
design methodology and pragmatic considerations around 
feasibility and completion within a paediatric dataset.25 
This particular study is limited by the inability to blind the 
treatment allocation to the patients, their families or their 
treating physician due to the differences in medication 
administration route and the side effects commonly asso-
ciated with the study medication. Although the protocol 
advises that where possible blinding of an alternative clini-
cian to score disease assessment at each study visit should 
occur in order to obtain PROBE evaluation, this may 
be practically difficult in smaller centres where staff are 
familiar with the majority of their patient cohort.
EthICs And dIssEMInAtIon
The study is being conducted according to the principles of 
the Declarations of Helsinki and to date has been approved 
by all participating sites as listed within online supplemen-
tary table 1. Clinical trials authorisation and ethics approval 
has been obtained from the local ethics review commit-
tees of these participating nations and centres. The Stan-
dard Protocol Items: Recommendations for Interventional 
Trials guidelines26 were adhered to in the production of the 
protocol for this trial (see uploaded material for details).
Consent
Patients and their caregivers are provided with study- specific 
information including an explicit description of the study 
outline and alternatives for participation. It is made clear 
to all patients approached that declining to participate 
in the study will not jeopardise the quality of subsequent 
care received. After a period of consideration, if agreeable, 
the patient’s parent or caregiver is asked to sign consent 
forms with age- appropriate assent obtained from the child 
where relevant (see online supplementary appendix 1 for 
model consent forms). The signed forms are filed within 
the patient’s medical record with a copy provided to the 
participant and their caregiver. Consent will be obtained by 
site staff with the relevant training and who are identified as 
assigned on the delegation log. Participants taking part in 
the ancillary study will not be reconsented.
dissemination
Results of the study will be submitted for publication within 
a peer- reviewed journal. In accordance with the H2020 
general grant agreement, the dissemination process will 
ensure open access to the scientific publications resulting 
from this project. Journal authorship guidelines will be 
adhered to and there are no plans to use professional 
writers.
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